Backbone-Minimised Nanoplasmid DNA Systems Enable High-Titre AAV Production in Suspension HEK293 Platforms.

Hall L, Fiore MJ, Abramovich J, Kerridge C, Rahim AA, Rafiq QA, Massaro G

Open source

DOI
10.3390/pharmaceutics18070814
Published
2026 Jun 30
Container
Pharmaceutics
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/pharmaceutics18070814,
  title = {Backbone-Minimised Nanoplasmid DNA Systems Enable High-Titre AAV Production in Suspension HEK293 Platforms.},
  author = {Hall L and Fiore MJ and Abramovich J and Kerridge C and Rahim AA and Rafiq QA and Massaro G},
  year = {2026},
  journal = {Pharmaceutics},
  doi = {10.3390/pharmaceutics18070814},
  url = {https://doi.org/10.3390/pharmaceutics18070814}
}

RIS

TY  - JOUR
TI  - Backbone-Minimised Nanoplasmid DNA Systems Enable High-Titre AAV Production in Suspension HEK293 Platforms.
AU  - Hall L
AU  - Fiore MJ
AU  - Abramovich J
AU  - Kerridge C
AU  - Rahim AA
AU  - Rafiq QA
AU  - Massaro G
PY  - 2026
JO  - Pharmaceutics
DO  - 10.3390/pharmaceutics18070814
UR  - https://doi.org/10.3390/pharmaceutics18070814
ER  - 

APA

L, H., MJ, F., J, A., C, K., AA, R., QA, R., & G, M. (2026). Backbone-Minimised Nanoplasmid DNA Systems Enable High-Titre AAV Production in Suspension HEK293 Platforms.. Pharmaceutics. https://doi.org/10.3390/pharmaceutics18070814

Source records